GSK announces positive final stage results for two-drug HIV treatment

Wednesday, Feb 15, 2017

VIIV phase III results dolutegravir & rilpivirineAnnounces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

In sword studies, two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patientsHeadline results were announced in December 2016

Use of dolutegravir and rilpivirine as a two-drug regimen for hiv-1 maintenance therapy is investigational and not approved anywhere in world

Other News